Published in Gut on October 01, 2004
Atherogenic diet causes lethal ileo-ceco-colitis in cyclooxygenase-2 deficient mice. Prostaglandins Other Lipid Mediat (2007) 0.83
What is the origin of ulcerative colitis? Still more questions than answers. Postgrad Med J (2006) 0.80
A 3D Polymer Model for Future Nutrition Design Novel Nutrition Approach for Cystic Fibrosis, Ulcerative Colitis and Crohn's Disease. J Nanomedine Biotherapeutic Discov (2014) 0.76
Nutritional concerns in pediatric inflammatory bowel disease. Korean J Pediatr (2016) 0.75
The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therap Adv Gastroenterol (2016) 0.75
Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med (1992) 2.71
Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut (1994) 1.96
Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest (2003) 1.86
Detoxification of hydrogen sulfide and methanethiol in the cecal mucosa. J Clin Invest (1999) 1.82
Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res (2001) 1.80
Modern life' in the epidemiology of inflammatory bowel disease: a case-control study with special emphasis on nutritional factors. Eur J Gastroenterol Hepatol (1998) 1.80
Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol (2003) 1.77
Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut (2004) 1.77
In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology (1998) 1.74
Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology (2001) 1.71
The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut (2000) 1.65
Reducing sulfur compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis. Gastroenterology (1993) 1.58
Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis. Dig Dis Sci (1996) 1.54
Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Dig Dis Sci (1997) 1.52
Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol (2003) 1.51
Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand J Gastroenterol (2001) 1.39
Contribution of dietary protein to sulfide production in the large intestine: an in vitro and a controlled feeding study in humans. Am J Clin Nutr (2000) 1.35
Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol (2002) 1.30
Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut (1992) 1.30
Pre-illness dietary factors in inflammatory bowel disease. Gut (1997) 1.29
Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther (2001) 1.21
Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflamm Bowel Dis (2003) 1.16
Diet as a risk factor for the development of ulcerative colitis. Am J Gastroenterol (2000) 1.16
Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol (1999) 1.14
Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther (2003) 1.11
A new method for the determination of sulphide in gastrointestinal contents and whole blood by microdistillation and ion chromatography. Clin Chim Acta (2000) 1.10
Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and NF-kappaB. Am J Physiol Gastrointest Liver Physiol (2003) 1.09
Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol (1992) 1.07
Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease--a randomized, placebo-controlled, double-blind cross-over trial. J Intern Med Suppl (1989) 1.07
Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study. Aliment Pharmacol Ther (1998) 0.97
Decreased sulphur aminoacid intake in ulcerative colitis. Lancet (1998) 0.94
Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats. Clin Nutr (2003) 0.93
Bismuth subsalicylate markedly decreases hydrogen sulfide release in the human colon. Gastroenterology (1998) 0.92
Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation. Biochem Biophys Res Commun (2002) 0.89
A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment Pharmacol Ther (1993) 0.83
Effects of short-chain fatty acids on the inflamed colonic mucosa. Scand J Gastroenterol Suppl (1997) 0.80
A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment Pharmacol Ther (2002) 0.79
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2009) 3.22
Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun (2003) 2.10
The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut (2005) 1.91
Gut, inflammation and osteoporosis: basic and clinical concepts. Gut (2008) 1.61
Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut (2005) 1.53
CD1 expression on antigen-presenting cells. Curr Top Microbiol Immunol (2007) 1.42
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 1.41
A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut (2003) 1.19
Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol (2004) 1.14
Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus. J Virol (1999) 1.12
Cutting edge: peripheral neuropeptides attract immature and arrest mature blood-derived dendritic cells. J Immunol (2001) 1.12
A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis (2010) 1.08
Cooperation between GLI and JUN enhances transcription of JUN and selected GLI target genes. Oncogene (2009) 1.06
The hemagglutinin-esterase of mouse hepatitis virus strain S is a sialate-4-O-acetylesterase. J Virol (1999) 1.01
Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Int J Colorectal Dis (2002) 1.01
Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med (2005) 0.96
CD40 ligand-dependent maturation of human monocyte-derived dendritic cells by activated platelets. Int J Immunopathol Pharmacol (2003) 0.90
[Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseases. Consensus of the Austrian IBD Working Party]. Z Gastroenterol (2011) 0.88
Functional expression of chemokine receptor 2 by normal human eosinophils. J Allergy Clin Immunol (2001) 0.84
Dendritic cell migration in different micropore filter assays. Immunol Lett (2000) 0.83
Activation of caspase-3 by interferon alpha causes interleukin-16 secretion but fails to modulate activation induced cell death. Eur Cytokine Netw (2001) 0.80
IL-6 and arthritis: a detrimental or beneficial mediator? IDrugs (1998) 0.80
Interferons and their role In inflammation. Curr Pharm Des (1999) 0.79
Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients. Lancet (1999) 0.79
Interleukin-16 supports the migration of Langerhans cells, partly in a CD4-independent way. J Invest Dermatol (2001) 0.78
Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. Eur Cytokine Netw (1999) 0.77
Predicting mortality by the Glasgow alcoholic hepatitis score: the long awaited progress? Gut (2005) 0.76
Engagement of the Fc epsilon RI stimulates the production of IL-16 in Langerhans cell-like dendritic cells. J Immunol (2001) 0.76
Simultaneous solid phase extraction, derivatization, and gas chromatographic mass spectrometric quantification of thromboxane and prostacyclin metabolites, prostaglandins, and isoprostanes in urine. Anal Chem (1997) 0.75
[Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology]. Z Gastroenterol (2009) 0.75
[Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology]. Z Gastroenterol (2011) 0.75
Plasma levels of soluble Fas during treatment of chronic hepatitis C patients with interferon alpha. J Hepatol (1999) 0.75